Found 3802 clinical trials
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by
- 16 views
- 28 Oct, 2022
- 32 locations
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
- 8 views
- 14 Sep, 2022
- 76 locations
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously
- 10 views
- 23 Oct, 2022
- 80 locations
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously
- 1245 views
- 23 Oct, 2022
- 84 locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early
- 160 views
- 28 Oct, 2022
- 104 locations
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY) (PATHWAY)
The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),
- 11 views
- 11 Nov, 2022
- 39 locations
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)
The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …
- 10 views
- 18 Oct, 2022
- 53 locations
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)
Primary Objective: To evaluate the ability of dupilumab to reduce the need for rescue therapy with systemic corticosteroids (SCS) or surgery of AFRS in patients with AFRS who previously have had sino-nasal surgery Secondary Objectives: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population …
- 89 views
- 27 Jan, 2023
- 41 locations
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus (APATURA)
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in
- 10 views
- 25 Jan, 2023
- 6 locations
A trial evaluating TEPEZZA® in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The overall objective is to investigate the safety, tolerability and effect on insulin-like growth factor-1 (IGF-1), inflammatory and fibrotic biomarkers of TEPEZZA® administered once every 3 weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).
- 6 views
- 11 Aug, 2022
- 5 locations